American Society of Hirudotherapy

PROS1 (Cys228Tyr) missense mutation associated with mesenteric and pulmonary venous thromboembolism during the COVID-19 pandemic: a case report

Case report published in Frontiers in cardiovascular medicine (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Case reportClinical LiteratureHuang et al. · Frontiers in cardiovascular medicine, 2025

Abstract

BACKGROUND: Venous thromboembolism (VTE) is influenced by both genetic and acquired risk factors, with protein S (PS) deficiency recognized as a well-established inherited thrombophilia. Introduction: We report the case of a 32-year-old male patient presenting with mesenteric venous thrombosis and pulmonary embolism caused by a missense mutation in PROS1 during the COVID-19 pandemic. METHODS: The patient presented with pleuritic chest pain and low-grade fever 15 days after a confirmed COVID-19 infection. Despite initial treatment with glucocorticoids and a macrolide antibiotic, his symptoms worsened and his D-dimer level increased. CT pulmonary angiography confirmed an acute pulmonary embolism. RESULTS: Clinical history revealed a prior episode of mesenteric vein thrombosis and multiple acquired risk factors, including obesity, sedentariness, COVID-19 infection, glucocorticoid treatment, inflammatory response (elevated CRP and serum ferritin levels), and metabolic abnormalities (non-alcoholic fatty liver disease, hyperuricemia, and hyperlipidemia). Laboratory testing showed decreased PS activity, and genetic sequencing identified a heterozygous missense mutation in PROS1, c.683G>A (p.Cys228Tyr). The patient was treated with low-molecular-weight heparin (LMWH) followed by rivaroxaban. Discussion: No recurrence of VTE of bleeding events was observed during a one-year follow-up, suggesting effective management of thrombosis in the context of both inherited and acquired prothrombotic conditions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

A 32-year-old man developed mesenteric venous thrombosis and pulmonary embolism during COVID-19 and was found to carry a heterozygous PROS1 missense mutation (c.683G>A, p.Cys228Tyr); treatment with low-molecular-weight heparin followed by rivaroxaban showed no VTE recurrence over one year of follow-up.

Context

This single case report describes a 32-year-old man who developed mesenteric venous thrombosis and pulmonary embolism linked to a heterozygous PROS1 (Cys228Tyr) missense mutation causing protein S deficiency, against a backdrop of COVID-19 and multiple acquired risk factors; he was managed with low-molecular-weight heparin then rivaroxaban with no recurrence over one year of follow-up. The value is contextual rather than direct: it illustrates the inherited and acquired hypercoagulable states that define venous thromboembolism, the clinical territory in which the medicinal-leech anticoagulant tradition originates, since hirudin (the leech's salivary thrombin inhibitor) is the historical prototype that seeded modern direct anticoagulant drug discovery. The honest caveat is twofold: this is a single case report (the weakest evidence tier, hypothesis-generating only, not generalizable), and it studies conventional pharmacologic anticoagulants with no leech therapy or leech-derived agent involved, so it should be read only as background on the thrombosis problem space.

Citation

Reference (Vancouver style)

Huang J, Zhang Y, Yu H, Liu W. PROS1 (Cys228Tyr) missense mutation associated with mesenteric and pulmonary venous thromboembolism during the COVID-19 pandemic: a case report. Front Cardiovasc Med. 2025;12:1610580. doi:10.3389/fcvm.2025.1610580. PMID: 40771767

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 29, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.